Home › Compugen Presents Results For CGEN-15029 Immuno-Oncology Program
 

Keywords :   


Compugen Presents Results For CGEN-15029 Immuno-Oncology Program

2016-03-01 01:32:56| drugdiscoveryonline News Articles

In an oral presentation today at the New York Academy of Sciences' Emerging Approaches to Cancer Immunotherapy conference, John Hunter, Ph.D., Site Head and Vice President of Antibody R&D at Compugen USA, Inc., a wholly owned subsidiary of Compugen Ltd. (NASDAQ: CGEN), presented results for CGEN-15029, the lead internal program in the Company's immuno-oncology therapeutics pipeline.

Tags: results program presents presents results

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.07Tropical Storm Beryl Public Advisory Number 29A
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Atlantic Tropical Weather Outlook
06.07Eastern North Pacific Tropical Weather Outlook
05.07Tropical Storm Beryl Potential Storm Surge Flooding Map
05.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
05.07Tropical Storm Beryl Storm Surge Watch/Warning Map
05.07Tropical Storm Beryl Storm Surge Watch/Warning Map
More »